Fatal pulmonary fibrosis after rituximab administration
- PMID: 19396468
- DOI: 10.1007/s00467-009-1195-9
Fatal pulmonary fibrosis after rituximab administration
Abstract
Idiopathic nephrotic syndrome is the most frequent glomerular disease during childhood. Although immunosuppressive agents are usually effective, some severe cases remain difficult to treat. We describe a female patient with secondary steroid-resistant nephrotic syndrome who no longer responded to conventional treatment. Owing to cyclosporine toxicity, rituximab was administered. Three days after treatment the patient's clinical condition dramatically worsened and she developed acute respiratory distress. Despite all means used to treat her, she died 5 weeks after rituximab infusion. A pulmonary biopsy showed extensive fibrosis, while the alveolar epithelium was no longer visible.
Comment in
-
Severe respiratory adverse events associated with rituximab infusion.Pediatr Nephrol. 2010 Jun;25(6):1193. doi: 10.1007/s00467-009-1408-2. Epub 2009 Dec 19. Pediatr Nephrol. 2010. PMID: 20024586 No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
